 |
인쇄하기
취소
|
Viromed to announce Phase I study results of VM202
Viromed Co., Ltd. plans to present the phase I study results of VM202 (DNA-based medicine for ischemic disease including peripheral and coronary artery disease) in a forthcoming society in Seoul next month and in the United Stated next March.
In Korea, the phase I, dose-escalation study has commenced to asses the safety and tolerability in the patients with ischemic heart disease. This trial...
In Korea, the phase I, dose-escalation study has commenced to asses the safety and tolerability in the patients with ischemic heart disease. This trial...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.